Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.
An article from
Dive Brief
Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.
Published Aug. 26, 2026
Biohaven CEO Vlad Coric
Biohaven strikes $795M deal for commercial partner in epilepsy
SK Biopharm strikes $800m deal for epilepsy drug from Biohaven
Why Is Biohaven Stock Soaring Wednesday? - Biohaven (NYSE:BHVN)
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio
BioCryst is profitable. Now it wants to buy more rare disease drugs
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahead of key epilepsy trial data.
South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights to Biohaven’s Kv7 ion channel…
SK Biopharmaceuticals is staking nearly $800 million on rights to an epilepsy treatment from US biotech firm Biohaven, the…
RBC's $22 price target implies an upside of 74% for shares of Biohaven.
Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair eyes upcoming trial data.
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and…
